| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 196 | 2022 |
| Diabetic macular oedema treated with intravitreal anti‐vascular endothelial growth factor–2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following … D Hodzic‐Hadzibegovic, BA Sander, TJ Monberg, M Larsen, ... Acta Ophthalmologica 96 (3), 267-278, 2018 | 33 | 2018 |
| TIL therapy: facts and hopes TJ Monberg, TH Borch, IM Svane, M Donia Clinical Cancer Research 29 (17), 3275-3283, 2023 | 17 | 2023 |
| Glucose homeostasis in statin users—the LIFESTAT study T Morville, T Dohlmann, AB Kuhlman, T Monberg, M Torp, B Hartmann, ... Diabetes/Metabolism Research and Reviews 35 (3), e3110, 2019 | 10 | 2019 |
| 1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T … IM Svane, JM Santos, V Cervera-Carrascon, R Havunen, S Sorsa, ... Annals of Oncology 32, S864, 2021 | 8 | 2021 |
| LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma. M Nielsen, T Monberg, B Albieri, V Sundvold, O Rekdal, N Junker, ... Journal of Clinical Oncology 40 (16_suppl), 11567-11567, 2022 | 7 | 2022 |
| LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma M Nielsen, T Monberg, V Sundvold, B Albieri, D Hovgaard, MM Petersen, ... Oncoimmunology 13 (1), 2290900, 2024 | 2 | 2024 |
| 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a … TJ Monberg, S Pakola, B Dreno, V Cervera-Carrascon, E Ellebæk, ... Immuno-Oncology and Technology 20, 2023 | 2 | 2023 |
| 749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors–Interim results J Santos, I Svane, K Peltola, T Alanko, R Korpisaari, S Juteau, M Jaakkola, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 1 | 2023 |
| Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes. DCA Quixabeira, E Jirovec, J Clubb, S Pakola, JM Santos, K Jalkanen, ... Journal of Clinical Oncology 42 (16_suppl), 2658-2658, 2024 | | 2024 |
| Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial RMT Ten Ham, MW Rohaan, I Jedema, R Kessels, W Stegeman, ... Journal for Immunotherapy of Cancer 12 (3), 2024 | | 2024 |
| 715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials V Cervera-Carrascon, I Svane, K Peltola, T Alanko, R Korpisaari, S Juteau, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Diabetic macular oedema treated with intravitreal anti‐vascular endothelial growth factor–2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following … BA Sander, TJ Monberg, D Hodzic‐Hadzibegovic, M Larsen, ... Acta Ophthalmologica (1755375X) 96 (3), 2018 | | 2018 |
| Diabetic macular edema treated with ranibizumab in a large single center unselected population of 566 diabetic patients with a 2-4 year follow-up Delila Hodzic-Hadzibegovic1, 2 … D Hodzic-Hadzibegovic, BA Sander, TJ Monberg, M Larsen, ... Investigative Ophthalmology & Visual Science 58 (8), 1911-1911, 2017 | | 2017 |
